Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
INOVIO PHARMACEUTICALS, INC. entered into Underwriting Agreement with Piper Sandler & Co. valued at Public offering of 12,500,000 shares of common stock and Series A and Series B warrants with an opti (effective 2026-04-02).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Piper Sandler & Co.
- Value
- Public offering of 12,500,000 shares of common stock and Series A and Series B warrants with an opti
- Effective
- 2026-04-02
Exact text from the filing
On April 2, 2026, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Piper Sandler & Co., as representative of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale by the Company in a public offering of 12,500,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and accompanying Series A warrants to purchase up to 12,500,000 shares of its Common Stock (or pre-funded warrants, each representing the right to purchase one share of Common Stock at an exercise price of $0.001 (the “ Pre-Funded Warrants ”) in lieu thereof) at an exercise price of $1.40 per share of common stock (or $1.399 per Pre-Funded Warrant) (the “ Series A Warrants ”) and Series B warrants to purchase up to 12,500,000 shares of its Common Stock (or Pre-Funded Warrants in lieu thereof) at an exercise price of $1.40 per share of Common S
View on SEC.gov